Identification of a KLF5-dependent program and drug development for skeletal muscle atrophy
Skeletal muscle atrophy is caused by various conditions, including aging, disuse related to a sedentary lifestyle and lack of physical activity, and cachexia. Our insufficient understanding of the molecular mechanism underlying muscle atrophy limits the targets for the development of effective pharm...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 118; no. 35; p. 1 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
31.08.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Skeletal muscle atrophy is caused by various conditions, including aging, disuse related to a sedentary lifestyle and lack of physical activity, and cachexia. Our insufficient understanding of the molecular mechanism underlying muscle atrophy limits the targets for the development of effective pharmacologic treatments and preventions. Here, we identified Krüppel-like factor 5 (KLF5), a zinc-finger transcription factor, as a key mediator of the early muscle atrophy program. KLF5 was up-regulated in atrophying myotubes as an early response to dexamethasone or simulated microgravity in vitro. Skeletal muscle-selective deletion of
significantly attenuated muscle atrophy induced by mechanical unloading in mice. Transcriptome- and genome-wide chromatin accessibility analyses revealed that KLF5 regulates atrophy-related programs, including metabolic changes and E3-ubiquitin ligase-mediated proteolysis, in coordination with Foxo1. The synthetic retinoic acid receptor agonist Am80, a KLF5 inhibitor, suppressed both dexamethasone- and microgravity-induced muscle atrophy in vitro and oral Am80 ameliorated disuse- and dexamethasone-induced atrophy in mice. Moreover, in three independent sets of transcriptomic data from human skeletal muscle,
expression significantly increased with age and the presence of sarcopenia and correlated positively with the expression of the atrophy-related ubiquitin ligase genes
and
These findings demonstrate that KLF5 is a key transcriptional regulator mediating muscle atrophy and that pharmacological intervention with Am80 is a potentially preventive treatment. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Author contributions: T.N. and Y.O. designed research; L.L., H. Koike, T.O., S.H., F.K., T.N., and Y.O. performed research; A.K. and H. Kagechika contributed new reagents/analytic tools; L.L., H. Koike, A.K., I.M., and Y.O. analyzed data; and L.L., H. Koike, I.M., and Y.O. wrote the paper. Edited by Margaret Buckingham, Institut Pasteur, Paris, France, and approved July 20, 2021 (received for review February 15, 2021) |
ISSN: | 0027-8424 1091-6490 |
DOI: | 10.1073/pnas.2102895118 |